Innovation in immunomodulation

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is  developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.

Latest news


ImCheck Therapeutics is one of the 8 young French biotechs selected in the French Tech 120 program!
Leadership & Corporate 
Read more
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
Financial & Business 
Read more
ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic
Financial & Business 
Read more

Upcoming events


Immuno-oncology Summit Europe

From  Feb 09, 2020  to  Mar 12, 2020 

Read more

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020

From  Mar 12, 2020  to  Mar 13, 2020 

Read more

BioCapital Europe

On  Mar 12, 2020 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and news